News - Erbitux


Current filters:


Popular Filters

European Commission backs wider use of Merck’s Erbitux

European Commission backs wider use of Merck’s Erbitux


Merck Serono, the biopharmaceutical division of Germany’s Merck KGaA, has gained European Commission…

ErbituxEuropeMerck KGaAMerck SeronoOncologyPharmaceuticalRegulation

Merck KGaA improves guidance with strong third quarter results

Merck KGaA improves guidance with strong third quarter results


Germany’s Merck KGaA (MRK: DE) has posted solid organic revenue growth of 4.7% for the third quarter…

BiotechnologyErbituxEuropeFinancialMerck KGaAMerck SeronoPharmaceuticalRebif

Highlights from European Cancer Congress on Kadcyla, Yervoy, Erbitux and Somatuline


A host of new oncology data was presented at the European Cancer Congress in Amsterdam, the Netherlands,…

Bristol-Myers SquibbErbituxEuropeIpsenKadcylaMerck KGaAOncologyPharmaceuticalResearchRocheSomatulineYervoy

US firms establish strategic partnership around biosimilars


Privately-held Oncobiologics has formed a broad strategic partnership with fellow USA-based inVentiv…

AvastinBiotechnologyErbituxGenericsHerceptinHumiraImmunologicalsinVentive HealthOncobiologicsOncologyProductionResearchRituxan

Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux


Australian drug developer Alchemia (ASX: ACL) and Merck Serono, a subsidiary of Germany's Merck KGaA…

AlchemiaBiotechnologyErbituxHA-IrinotecanMerck KGaAMerck SeronoOncologyPharmaceuticalResearch

US FDA approves Erbitux as first-line treatment in KRAS wild-type EGFR


US drug majors Eli Lilly (NYSE: LLY) and Bristol-Myers Squibb (NYSE: BMY) on Friday received full approval…

Bristol-Myers SquibbEli LillyErbituxNorth AmericaOncologyPharmaceuticalQiagenRegulation

News briefs from Merck KGaA and Sanofi


German drug major Merck KGaA )MRK: DE) revealed this morning that its Phase III EXPAND trial, which assessed…

cilengitideErbituxManagementMerck KGaAMergers & AcquisitionsPharmaceuticalResearchSanofi

Adding cetuximab following colon cancer surgery does not improve disease-free survival


Adding the drug cetuximab, the active ingredient of Erbitux from German drug major Merck KGaA (MRK: DE),…

cetuximabErbituxMerck KGaAOncologyPharmaceuticalResearch

Chinese colorectal cancer drug market forecast to grow to over $400 million in 2016


The colorectal cancer drug market in China will grow from a value of $261 million in 2011 to $404 million…

Asia-PacificAvastinErbituxMarkets & MarketingMerck KGaAOncologyPharmaceuticalRoche

Added indication for Bristol-Myers’ Erbitux approved by FDA


The US Food and Drug Administration yesterday approved US drug major Bristol-Meyers Squibb’s (NYSE:…

Bristol-Myers SquibbErbituxNorth AmericaOncologyPharmaceuticalRegulation

Erbitux and Gilenya added to Australia’s PBS listing


More than 400,000 Australians will benefit from new subsidized medicines, effective September 1, as Minister…

Asia-PacificErbituxGilenyaMerck KGaANeurologicalNovartisOncologyPharmaceuticalPricingRegulation

Back to top